EIF2AK3 and cancer: Pretreatment of cancer cells with LY294002 (phosphoinositide 3-kinase inhibitor) or PD98059 (mitogen-activated protein kinase inhibitor) further reduced the expression of pAKT and pERK in progesterone-calcitriol combination-treated cells.